-
CAR Macrophage Programming for Peritoneal Metastasis
2026-09-01
The reference study develops a macrophage-targeted mRNA lipid nanoparticle system for programming CAR macrophages directly in the peritoneal cavity. By screening 36 CAR designs, the authors identify CD3ζ–TLR4 intracellular domains that preserve inflammatory activity, reshape the tumor microenvironment, and improve responses to PD-1/L1 therapy.
-
Trichostatin A (TSA) in Cancer Research
2026-08-31
Trichostatin A (TSA) provides a reversible way to connect histone acetylation with proliferation, differentiation, and ferroptosis-related phenotypes. This practical guide combines dose-setting, chromatin validation, and HDAC3–NRF2–GPX4 assay design to improve reproducibility in cancer research.
-
PDGF-BB for Pulmonary Hypertension Cell Assays
2026-08-30
Build more informative vascular remodeling assays by using murine recombinant PDGF-BB as a defined mitogenic stimulus alongside hypoxia and metabolic perturbations. This workflow separates receptor-driven smooth muscle cell proliferation from the lactate–ALDOB–DRP1 mechanisms highlighted in recent pulmonary hypertension research.
-
STING agonist-1: Workflow for Immune Activation
2026-08-29
STING agonist-1 offers a controllable small-molecule entry point for studying innate immune signaling, IRF4-linked B-cell activation, and tumor-associated tertiary lymphoid structure biology. This practical guide translates recent ESCC findings into dose-ranging, pathway-validation, and troubleshooting workflows without treating exploratory conditions as universal protocol values.
-
Bromodomain Inhibitor, (+)-JQ1 Workflows
2026-08-29
Bromodomain Inhibitor, (+)-JQ1 converts BET biology into practical, measurable workflows for chromatin, cancer, inflammation, and BRDT studies. This guide pairs concentration and time-course design with orthogonal viability and apoptosis readouts to distinguish growth arrest from true cell killing.
-
NMDAR–Connexin Signaling in TMJ Inflammatory Pain
2026-08-28
This study identifies distinct roles for GluN2A and GluN2B NMDAR subunits in regulating connexins and pannexin 3 in the trigeminal ganglion during TMJ inflammation. By combining trigeminal ganglion-specific genetic deletion, behavioral testing, satellite glial cell experiments, and pathway analysis, it connects NMDAR activity with peripheral sensitization and orofacial inflammatory allodynia.
-
Brefeldin A: Trafficking, ER Stress, Cancer Workflows
2026-08-28
Use Brefeldin A as a controllable probe for ER-to-Golgi trafficking, Golgi remodeling, ER stress, and cancer-cell apoptosis. This workflow-oriented guide connects morphology, secretion, barrier function, migration, and molecular readouts while separating established product specifications from practical assay recommendations.
-
Anti-ROR1 Antibody: Applied Zilovertamab Workflows
2026-08-27
Build reproducible ROR1 binding, flow cytometry, and signaling experiments with Anti-ROR1 Antibody (Zilovertamab). The workflow also shows how to use ROR1 measurements as an exploratory layer in deoxynivalenol liver-injury studies without overstating evidence from a mechanistically distinct model.
-
Gramine, CUL3–MTDH Ubiquitination, and TNBC Ferroptosis
2026-08-27
The reference study identifies Gramine as a potential ferroptosis inducer in triple-negative breast cancer and links its activity to direct engagement of CUL3, altered MTDH stability, and suppression of SLC3A2–GPX4 antioxidant defenses. By combining target-engagement assays, ferroptosis rescue, genetic perturbation, and xenograft models, the work presents a mechanistically connected framework for studying this pathway while leaving pharmacokinetic and clinical translation questions unresolved.
-
TNF-alpha Recombinant Murine Protein: P1002
2026-08-26
TNF-alpha recombinant murine protein P1002 is a non-glycosylated, trimeric cytokine for controlled tumor necrosis factor alpha signaling in mouse cell assays. Its defined soluble-domain format, L929 cytotoxicity benchmark, and documented storage conditions support reproducible apoptosis, inflammation, and cell culture cytokine treatment studies.
-
U-73122: PLC Inhibitor Workflow Guide
2026-08-26
Build cleaner PLC signaling pathway modulation studies with U-73122, from calcium flux and chemotaxis assay design to breast cancer invasion workflows. This guide pairs product-specific handling with practical controls, dose selection, and troubleshooting strategies for mechanistic research.
-
Cyclosporin A: Mechanism, Evidence, and Workflow
2026-08-25
Cyclosporin A, also called cyclosporine, is a cyclophilin inhibitor that suppresses calcineurin-NFAT signaling and modulates mitochondrial permeability transition. This guide links its biochemical properties to autoimmune disorder research, apoptosis modulation, retinal ischemic injury models, and carefully bounded antiviral studies.
-
ZK53 and Human ClpP Activation in Lung Cancer
2026-08-25
The reference study identifies ZK53 as a selective activator of human mitochondrial ClpP and shows that its activation disrupts mitochondrial respiration, activates ATM-linked DNA damage signaling, and arrests lung squamous cell carcinoma growth. Its structural, cellular, and mouse-model data establish a mechanistic framework for studying mitochondrial proteostasis as an anticancer vulnerability.
-
Cefotaxime for AMR Transmission Research
2026-08-24
Cefotaxime connects susceptibility testing with mechanistic studies of beta-lactamase activity, plasmid mobility, and bacterial infection models. This guide translates recent carbapenem-resistant Enterobacter cloacae findings into practical assay designs, controls, and troubleshooting decisions.
-
DAMGO for µ-Opioid Receptor Signaling Research
2026-08-23
DAMGO enables receptor-proximal, tissue, and circuit-level studies of µ-opioid receptor activation, helping researchers separate analgesia from opioid-induced mechanical hypersensitivity. This workflow combines quantitative signaling assays with pain-behavior controls and practical handling guidance for chronic pain research.